Serum Concentration of Selected Angiogenesis-Related Molecules Differs among Molecular Subtypes, Body Mass Index and Menopausal Status in Breast Cancer Patients
Abstract
:1. Introduction
2. Patients and Methods
2.1. Study Design
2.2. Patient Selection and Data
2.3. Sample Preparation
2.4. Enzyme-Linked Immunosorbent Assay (ELISA)
2.5. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Feig, W.B.; Ching, D.C. (Eds.) The MD Anderson Surgical Oncology Handbook, 6th ed.; University of Texas MD Anderson Cancer Center: Houston, TX, USA, 2019; ISBN 978-1-4963-5815-8. [Google Scholar]
- Winters, S.; Martin, C.; Murphy, D.; Shokar, K.N. Breast Cancer Epidemiology, Prevention, and Screening. Prog. Mol. Biol. Transl. Sci. 2017, 151, 1–32. [Google Scholar] [PubMed]
- Madu, C.O.; Wang, S.; Madu, C.O.; Lu, Y. Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment. J. Cancer 2020, 11, 4474–4494. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.Q.; Chen, W.L.; Zhang, F.; Wei, X.L.; Zeng, D.; Liang, Y.K.; Wu, J.D.; Zhang, L.Y.; Guo, C.P.; Zeng, H.C.; et al. Over-expression of both VEGF-C and Twist predicts poor prognosis in human breast cancer. Clin. Transl. Oncol. 2019, 21, 1250–1259. [Google Scholar] [CrossRef]
- Yotsumoto, F.; Tokunaga, E.; Oki, E.; Maehara, Y.; Yamada, H.; Nakajima, K.; Nam, S.O.; Miyata, K.; Koyanagi, M.; Doi, K.; et al. Molecular hierarchy of heparin-binding EGF-like growth factor-regulated angiogenesis in triple-negative breast cancer. Mol. Cancer Res. 2013, 11, 506–517. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yotsumoto, F.; Oki, E.; Tokunaga, E.; Maehara, Y.; Kuroki, M.; Miyamoto, S. HB-EGF orchestrates the complex signals involved in triple-negative and trastuzumab-resistant breast cancer. Int. J. Cancer 2010, 127, 2707–2717. [Google Scholar] [CrossRef] [PubMed]
- Lian, C.; Ruan, L.; Shang, D.; Wu, Y.; Lu, P.; Lü, P.; Yang, Y.; Wei, Y.; Dong, X.; Ren, D.; et al. Heparin-Binding Epidermal Growth Factor-Like Growth Factor as a Potent Target for Breast Cancer Therapy. Cancer Biother. Radiopharm. 2016, 31, 85–90. [Google Scholar] [CrossRef]
- Jansson, S.; Aaltonen, K.; Bendahl, P.O.; Falck, A.K.; Karlsson, M.; Pietras, K.; Rydén, L. The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence. Breast Cancer Res. Treat. 2018, 169, 231–241. [Google Scholar] [CrossRef] [Green Version]
- Yokoyama, Y.; Mori, S.; Hamada, Y.; Hieda, M.; Kawaguchi, N.; Shaker, M.; Tao, Y.; Yoshidome, K.; Tsujimoto, M.; Matsuura, N. Platelet-derived growth factor regulates breast cancer progression via β-catenin expression. Pathobiology 2011, 78, 253–260. [Google Scholar] [CrossRef]
- Carvalho, I.; Milanezi, F.; Martins, A.; Reis, M.R.; Schmitt, F. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res. 2005, 7, 788–795. [Google Scholar] [CrossRef] [Green Version]
- Jansson, S.; Bendahl, P.O.; Grabau, D.A.; Falck, A.K.; Fernö, M.; Aaltonen, K.; Rydén, L. The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer. PLoS ONE 2014, 9, e102176. [Google Scholar] [CrossRef]
- Ghosh, S.; Sullivan, A.C.; Zerkowski, P.M.; Molinaro, M.A.; Rimm, L.D.; Camp, L.R.; Chung, G.G. High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Hum. Pathol. 2008, 39, 1835–1843. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Perrot-Applanat, M.; Di Benedetto, M. Autocrine functions of VEGF in breast tumor cells: Adhesion, survival, migration and invasion. Cell Adhes. Migr. 2012, 6, 547–553. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fujii, T.; Hirakata, T.; Kurozumi, S.; Tokuda, S.; Nakazawa, Y.; Obayashi, S.; Yajima, R.; Oyama, T.; Shirabe, K. VEGF-A Is Associated with the Degree of TILs and PD-L1 Expression in Primary Breast Cancer. Vivo 2020, 34, 2641–2646. [Google Scholar] [CrossRef]
- Dumond, A.; Pagès, G. Neuropilins, as Relevant Oncology Target: Their Role in the Tumoral Microenvironment. Front. Cell Dev. Biol. 2020, 8, 662. [Google Scholar] [CrossRef]
- Yasuoka, H.; Kodama, R.; Tsujimoto, M.; Yoshidome, K.; Akamatsu, H.; Nakahara, M.; Inagaki, M.; Sanke, T.; Nakamura, Y. Neuropilin-2 expression in breast cancer: Correlation with lymph node metastasis, poor prognosis, and regulation of CXCR4 expression. BMC Cancer 2009, 9, 220. [Google Scholar] [CrossRef] [Green Version]
- Arpel, A.; Gamper, C.; Spenlé, C.; Fernandez, A.; Jacob, L.; Baumlin, N.; Laquerriere, P.; Orend, G.; Crémel, G.; Bagnard, D. Inhibition of primary breast tumor growth and metastasis using a neuropilin-1 transmembrane domain interfering peptide. Oncotarget 2016, 7, 54723–54732. [Google Scholar] [CrossRef] [PubMed]
- World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2013, 310, 2191–2194. [CrossRef] [Green Version]
- Schneider, P.B.; Miller, D.K. Angiogenesis of Breast Cancer. J. Clin. Oncol. 2005, 23, 1782–1790. [Google Scholar] [CrossRef]
- Barron, A.G.; Goua, M.; Wahle, W.J.K.; Bermano, G. Circulating levels of angiogenesis-related growth factors in breast cancer: A study to profile proteins responsible for tubule formation. Oncol. Rep. 2017, 38, 1886–1894. [Google Scholar] [CrossRef] [Green Version]
- Bottrell, A.; Meng, Y.H.; Najy, J.A.; Hurst, N., Jr.; Kim, S.; Kim, J.C.; Kim, E.S.; Moon, A.; Kim, E.J.; Park, S.Y.; et al. An oncogenic activity of PDGF-C and its splice variant in human breast cancer. Growth Factors 2019, 37, 131–145. [Google Scholar] [CrossRef]
- Kim, S.; You, D.; Jeong, Y.; Yoon, S.Y.; Kim, S.; Lee, J.E. Inhibition of platelet-derived growth factor C and their receptors additionally increases doxorubicin effects in triple-negative breast cancer cells. Eur. J. Pharmacol. 2021, 895, 173868. [Google Scholar] [CrossRef] [PubMed]
- Crawford, Y.; Kasman, I.; Yu, L.; Zhong, C.; Wu, X.; Modrusan, Z.; Kaminker, J.; Ferrara, N. PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment. Cancer Cell 2009, 15, 21–34. [Google Scholar] [PubMed] [Green Version]
- Calle, E.E.; Rodriguez, C.; Walker-Thurmond, K.; Thun, J.M. Overweight, Obesity, and Mortality from Cancer in a Prospectively Studied Cohort of U.S. Adults. N. Engl. J. Med. 2003, 348, 1625–1638. [Google Scholar] [CrossRef] [Green Version]
- Mendonca, F.; Soares, R. Obesity and cancer phenotype: Is angiogenesis a missed link? Life Sci. 2015, 139, 16–23. [Google Scholar]
- Gu, J.W.; Young, E.; Patterson, G.S.; Makey, L.K.; Wells, J.; Huang, M.; Tucker, B.K.; Miele, L. Postmenopausal obesity promotes tumor angiogenesis and breast cancer progression in mice. Cancer Biol. Ther. 2011, 11, 910–917. [Google Scholar] [CrossRef] [PubMed]
- Matsumoto, S.; Kishida, K.; Shimomura, I.; Maeda, N.; Nagaretani, H.; Matsuda, M.; Nishizawa, H.; Kihara, S.; Funahashi, T.; Matsuzawa, Y. Increased plasma HB-EGF associated with obesity and coronary artery disease. Biochem. Biophys. Res. Commun. 2002, 292, 781–786. [Google Scholar] [CrossRef]
- Trédan, O.; Lacroix-Triki, M.; Guiu, S.; Mouret-Reynier, M.A.; Barrière, J.; Bidard, F.C.; Braccini, A.L.; Mir, O.; Villanueva, C.; Barthélémy, P. Angiogenesis and tumor microenvironment: Bevacizumabin the breast cancer model. Target. Oncol. 2015, 10, 189–198. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.; Tamimi, M.R.; Collins, C.L.; Schnitt, J.S.; Gilmore, L.H.; Connolly, L.J.; Colditz, A.G. The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: Results from the Nurses’ Health Study. Breast Cancer Res. Treat. 2011, 129, 175–184. [Google Scholar] [CrossRef] [Green Version]
- Dent, S.F. The role of VEGF in triple-negative breast cancer: Where do we go from here? Ann. Oncol. 2009, 20, 1615–1617. [Google Scholar] [CrossRef]
- Linderholm, B.K.; Hellborg, H.; Johansson, U.; Elmberger, G.; Skoog, L.; Lehtio, J.; Lewensohn, R. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann. Oncol. 2009, 20, 1639–1646. [Google Scholar] [CrossRef]
Healthy | Breast Cancer Patients | ||
---|---|---|---|
Median (Interquartile Range) | Median (Interquartile Range) | p-Value | |
Total | N = 31 | N = 205 | |
VEGF (pg/mL) | 242.8 (113–437.4) | 270.8 (144.3–407) | 0.652 |
HB-EGF (pg/mL) | 142.3 (118.8–173.7) | 128.9 (100.5–172.6) | 0.152 |
PDGF-CC (pg/mL) | 985.8 (752.9–1203) | 1032.5 (824–1222.5) | 0.333 |
NRP-1 (pg/mL) | 264.9 (194.2–311.5) | 257.7 (218.3–301.1) | 0.698 |
VEGF (pg/mL) | HB-EGF (pg/mL) | PDGF-CC (pg/mL) | NEUROPILIN-1 (pg/mL) | ||
---|---|---|---|---|---|
Ν | Median (Interquartile Range) | Median (Interquartile Range) | Median (Interquartile Range) | Median (Interquartile Range) | |
Total | |||||
Luminal A | 60 | 249.3 (159.9–377.7) | 137.7 (102.8–169.9) | 1004 (776.7–1350.3) | 261.1 (214.1–312.3) |
Luminal B | 75 | 316.5 (145.4–449) | 128.4 (99–158.6) | 1060 (836.9–1263) | 255 (221.2–305.8) |
Luminal B (HER2−) | 51 | 337.2 (166.4–449) | 121.2 (98.9–157.8) | 1018 (793.3–1263) | 245.1 (221.2–294) |
Luminal B (HER2+) | 24 | 261.6 (133.5–521.9) | 138.2 (102.4–166.6) | 1156 (968.1–1254.5) | 274.3 (225.1–333.4) |
Triple Negative | 33 | 337.9 (198.9–478.8) | 121.8 (89.3–189.4) | 984.7 (768.8–1161.5) | 242.3 (199.2–288.5) |
HER2+ | 19 | 273.6 (114.3–380.7) | 117.9 (102.4–158.8) | 951.7 (736.7–1220) | 250.1 (231.7–323) |
Healthy | 31 | 242.8 (113–437.4) | 142.3 (118.8–173.7) | 985.8 (752.9–1203) | 264.9 (194.2–311.5) |
VEGF | HB-EGF | |||
Median (Interquartile Range) | p-Value | Median (Interquartile Range) | p-Value | |
Grade | 0.757 | 0.551 | ||
1 | 303.0 (114.4–437.7) | 125.5 (87.1–152.3) | ||
2 | 266.2 (145.4–398.8) | 129.3 (101.1–165.4) | ||
3 | 311.5 (143.5–416.4) | 127.7 (99.4–178.2) | ||
Stage | 0.365 | 0.219 | ||
Ι | 310 (166–431) | 129 (87–160) | ||
ΙΙ | 229 (100–374) | 118 (101–158) | ||
ΙΙΙ | 337 (216–398) | 142 (124–210) | ||
ΙV | 267 (130–472) | 119 (91–172) | ||
PDGF-CC | NEUROPILIN-1 | |||
Median (Interquartile Range) | p-Value | Median (Interquartile Range) | p-Value | |
Grade | 0.731 | 0.585 | ||
1 | 948.7 (719.8–1265.0) | 271.3 (249.3–284.3) | ||
2 | 1001.0 (793.3–1215.0) | 247.3 (213.7–300.5) | ||
3 | 1041.0 (850.8–1201.0) | 264.1 (223.8–321.9) | ||
Stage | 0.169 | 0.947 | ||
Ι | 965 (762–1.189) | 264 (215–295) | ||
ΙΙ | 1.009 (905–1.188) | 260 (234–290) | ||
ΙΙΙ | 1.171 (934–1.354) | 250 (206–322) | ||
ΙV | 1.007 (720–1.143) | 242 (218–350) |
BMI | |||
---|---|---|---|
BMI < 25 kg/m2 | BMI ≥ 25 kg/m2 | ||
Median (Interquartile Range) | Median (Interquartile Range) | p-Value | |
Healthy | |||
VEGF | 211.1 (91.6–315.3) | 292.9 (156.3–502.1) | 0.224 |
HB-EGF | 130.4 (108.8–151.1) | 155.2 (125.9–190.0) | 0.077 |
PDGF-CC | 1026.5 (631.3–1240.8) | 938.9 (759.3–1126.0) | 0.790 |
NEUROPILIN-1 | 303.8 (193.3–332.7) | 233.8 (190.4–270.2) | 0.142 |
Breast Cancer | |||
VEGF | 212.2 (104.2–375.2) | 280.5 (168.7–374.2) | 0.049 |
HB-EGF | 111.3 (88.1–149.2) | 142.6 (112.2–179.8) | <0.001 |
PDGF-CC | 1009.0 (758.1–1211.0) | 1034.0 (885.0–1315.0) | 0.275 |
NEUROPILIN-1 | 254.5 (214.4–313.6) | 249.8 (213.7–300.5) | 0.670 |
IDC | |||
VEGF | 212.9 (123.3–385.7) | 306.7 (185.3–402.5) | 0.084 |
HB-EGF | 116.4 (87.4–152.2) | 141.3 (109.2–181.5) | 0.004 |
PDGF-CC | 1018.5 (742.8–1206.0) | 1027.5 (874.0–1244.0) | 0.493 |
NEUROPILIN-1 | 251.5 (214.4–303.1) | 248.3 (220.5–301.8) | 0.908 |
ILC | |||
VEGF | 174.6 (72.3–271.8) | 270.2 (227.8–371.4) | 0.035 |
HB-EGF | 110.2 (95.7–173.6) | 129.3 (113.7–162.2) | 0.376 |
PDGF-CC | 985.4 (739.5–1267.8) | 1034.0 (867.7–1560.5) | 0.376 |
NEUROPILIN-1 | 238.7 (213.8–321.9) | 213.7 (185.3–321.8) | 0.295 |
Lum B (HER2+) | |||
VEGF | 145.4 (91.2–193.9) | 379.4 (256.9–795.5) | 0.008 |
HB-EGF | 128.2 (92.6–144.7) | 142.6 (117.4–163.8) | 0.094 |
PDGF-CC | 1065.0 (808.4–1229.0) | 1183.0 (988.4–1522.5) | 0.161 |
NEUROPILIN-1 | 279.6 (229.4–351.9) | 252.5 (185.4–305.5) | 0.297 |
Lum B (HER2−) | |||
VEGF | 224.4 (128.4–471.5) | 348.4 (126.1–424.8) | 0.626 |
HB-EGF | 118.7 (86.4–174.2) | 134.4 (105.3–159.5) | 0.516 |
PDGF-CC | 1108.0 (790.5–1315.0) | 1025.0 (905.9–1346.8) | 0.850 |
NEUROPILIN-1 | 255.0 (214.6–329.6) | 240.5 (223.2–288.8) | 0.588 |
HER2+ | |||
VEGF | 135.8 (128.0–380.7) | 268.9 (74.4–319.4) | 0.536 |
HB-EGF | 114.0 (102.4–189.6) | 134.8 (110.7–161.7) | 0.536 |
PDGF-CC | 951.7 (685.5–1171.0) | 1041.0 (799.6–1256.0) | 0.999 |
NEUROPILIN-1 | 250.1 (230.5–323.0) | 249.8 (232.7–332.2) | 0.837 |
TN | |||
VEGF | 232.4 (82.7–252.1) | 343.7 (240.6–412.9) | 0.083 |
HB-EGF | 92.6 (56.0–111.1) | 141.4 (110.1–198.9) | 0.010 |
PDGF-CC | 960.8 (596.0–1043.0) | 974.3 (827.4–1164.8) | 0.182 |
NEUROPILIN-1 | 238.6 (183.2–267.9) | 247.1 (205.3–290.8) | 0.299 |
Healthy | Breast Cancer Patients | ||
---|---|---|---|
Median (Interquartile Range) | Median (Interquartile Range) | p-Value | |
Premenopause | |||
VEGF (pg/mL) | 239.2 (123.3–413.4) | 240 (128.4–317.6) | 0.988 |
HB-EGF (pg/mL) | 144.4 (137.1–176.5) | 125.2 (94.7–171.2) | 0.039 |
PDGF-CC (pg/mL) | 1048 (920.3–1228) | 1077.5 (885–1265) | 0.981 |
NRP-1 (pg/mL) | 271.1 (207.1–324.1) | 254.8 (210.6–293.4) | 0.278 |
Postmenopause | |||
VEGF (pg/mL) | 259.9 (98–523.6) | 287.5 (161.8–409.2) | 0.906 |
HB-EGF (pg/mL) | 120.7 (114–162.1) | 129.3 (102.4–174.2) | 0.995 |
PDGF-CC (pg/mL) | 835.8 (622.6–1105) | 984.7 (800.6–1199) | 0.040 |
NRP-1 (pg/mL) | 237.7 (189.1–291.7) | 260.4 (221.2–305.8) | 0.129 |
VEGF | HB-EGF | PDGF-CC | NRP-1 | |
---|---|---|---|---|
Premenopause | p-Value | p-Value | p-Value | p-Value |
IDC vs. Healthy | 0.674 | 0.023 | 0.769 | 0.355 |
ILC vs. Healthy | 0.634 | 0.396 | 0.711 | 0.220 |
DCIS vs. Healthy | 0.493 | 0.543 | 0.543 | 0.880 |
IDC vs. ILC | 0.485 | 0.566 | 0.816 | 0.545 |
IDC vs. DCIS | 0.328 | 0.682 | 0.350 | 0.620 |
ILC vs. DCIS | 0.438 | 0.999 | 0.898 | 0.438 |
Postmenopause | ||||
IDC vs. Healthy | 0.690 | 0.956 | 0.045 | 0.144 |
ILC vs. Healthy | 0.575 | 0.360 | 0.227 | 0.227 |
DCIS vs. Healthy | 0.462 | 0.432 | 0.076 | 0.145 |
IDC vs. ILC | 0.136 | 0.202 | 0.390 | 0.830 |
IDC vs. DCIS | 0.107 | 0.319 | 0.619 | 0.340 |
ILC vs. DCIS | 0.657 | 0.094 | 0.363 | 0.511 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Balalis, D.; Tsakogiannis, D.; Kalogera, E.; Kokkali, S.; Tripodaki, E.; Ardavanis, A.; Manatakis, D.; Dimas, D.; Koufopoulos, N.; Fostira, F.; et al. Serum Concentration of Selected Angiogenesis-Related Molecules Differs among Molecular Subtypes, Body Mass Index and Menopausal Status in Breast Cancer Patients. J. Clin. Med. 2022, 11, 4079. https://doi.org/10.3390/jcm11144079
Balalis D, Tsakogiannis D, Kalogera E, Kokkali S, Tripodaki E, Ardavanis A, Manatakis D, Dimas D, Koufopoulos N, Fostira F, et al. Serum Concentration of Selected Angiogenesis-Related Molecules Differs among Molecular Subtypes, Body Mass Index and Menopausal Status in Breast Cancer Patients. Journal of Clinical Medicine. 2022; 11(14):4079. https://doi.org/10.3390/jcm11144079
Chicago/Turabian StyleBalalis, Dimitrios, Dimitrios Tsakogiannis, Eleni Kalogera, Stefania Kokkali, Elli Tripodaki, Alexandros Ardavanis, Dimitrios Manatakis, Dionysios Dimas, Nektarios Koufopoulos, Florentia Fostira, and et al. 2022. "Serum Concentration of Selected Angiogenesis-Related Molecules Differs among Molecular Subtypes, Body Mass Index and Menopausal Status in Breast Cancer Patients" Journal of Clinical Medicine 11, no. 14: 4079. https://doi.org/10.3390/jcm11144079